Cargando…

Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials

PURPOSE: We aimed to investigate whether the use of targeted agents (TAs) in advanced gastroesophageal cancer (GEC) increased the complete response (CR) and to assess the surrogate endpoints for survival in the targeted treatment of GEC by using a meta-analysis of randomized controlled trials (RCTs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Yanyang, Shen, Zhen, Sun, Jiancheng, Wang, Wu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237139/ https://www.ncbi.nlm.nih.gov/pubmed/30519098 http://dx.doi.org/10.2147/CMAR.S174063

Ejemplares similares

Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
por: Zheng, Jianqing, et al.
Publicado: (2022)

PRISMA – Practical meta-analysis of applying local triamcinolone acetonide injection for stenosis after esophageal cancer surgery
por: Wang, Wu, et al.
Publicado: (2018)

Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Endoscopic Variceal Sequential Ligation Does Not Increase Risk of Gastroesophageal Reflux Disease in Cirrhosis Patients
por: Tao, Jin, et al.
Publicado: (2019)

Therapeutic Advances in the Treatment of Gastroesophageal Cancers
por: Li, Jenny J., et al.
Publicado: (2023)

Targeted therapies for gastroesophageal cancers
por: Hsu, Andrew, et al.
Publicado: (2020)

Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis
por: Yan, Yin-Hong, et al.
Publicado: (2021)

Prognostic Value of Sarcopenia and Metabolic Parameters of (18)F-FDG-PET/CT in Patients with Advanced Gastroesophageal Cancer
por: Hinzpeter, Ricarda, et al.
Publicado: (2023)

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
por: Saeed, Anwaar, et al.
Publicado: (2021)

Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
por: Guo, Tao, et al.
Publicado: (2019)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Does Helicobacter pylori infection contribute to gastroesophageal reflux disease?
por: Spechler, S. J.
Publicado: (1998)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review
por: Li, Xiaoying, et al.
Publicado: (2021)

Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer
por: Swofford, Brenen P., et al.
Publicado: (2017)

Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer
por: Hinzpeter, Ricarda, et al.
Publicado: (2022)

Current Advancement on the Dynamic Mechanism of Gastroesophageal Reflux Disease
por: Zheng, Zhi, et al.
Publicado: (2021)

Current advances in the diagnosis and management of gastroesophageal reflux disease
por: Liang, Shu-Wei, et al.
Publicado: (2022)

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer
por: Puhr, Hannah Christina, et al.
Publicado: (2023)

Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials
por: Gu, Lihu, et al.
Publicado: (2022)

The Effects of Baclofen for the Treatment of Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Trials
por: Li, Shujie, et al.
Publicado: (2014)

A Meta-Analysis of Randomized Controlled Trials to Compare Long-Term Outcomes of Nissen and Toupet Fundoplication for Gastroesophageal Reflux Disease
por: Tian, Zhi-chao, et al.
Publicado: (2015)

Dietary protein intake and risk of ovarian cancer: evidence from a meta-analysis of observational studies
por: Pang, Yanyang, et al.
Publicado: (2018)

Active Choice Intervention Increases Advance Directive Completion: A Randomized Trial
por: Josephs, Michael, et al.
Publicado: (2018)

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis
por: Wang, Tongya, et al.
Publicado: (2022)

Statins and gastroesophageal reflux disease: A meta-analysis
por: Wijarnpreecha, K, et al.
Publicado: (2019)

Meta-analysis on the epidemiology of gastroesophageal reﬂux disease in China
por: Lu, Tai-Liang, et al.
Publicado: (2022)

Clinical Utility of (18)F-2-Fluoro-deoxy-d-glucose PET Imaging in Locally Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma
por: Cowzer, Darren, et al.
Publicado: (2023)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Maoxi, Zhong, et al.
Publicado: (2021)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma
por: Wang, Xin, et al.
Publicado: (2022)

Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies
por: Lynch, Emer, et al.
Publicado: (2023)

Targeted therapy in gastroesophageal cancers: past, present and future
por: Woo, Janghee, et al.
Publicado: (2015)

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer
por: Lam, Alfred King-yin, et al.
Publicado: (2022)

Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
por: Mehta, Rutika, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8bvcgjr5e72mvsmf5v5pkm07v